Credit: Syracuse University Syracuse, N.Y. – Syracuse University chemistry professor Dr. Robert P. Doyle has developed a new drug lead to treat type 2 diabetes in millions of patients who are seeking to better control their blood sugar without the common side effects of nausea, vomiting, and in select cases, undesired weight loss. Doyle’s research...
Tag: <span>Diabetes drug</span>
Post
Certain diabetes drugs may protect against serious kidney problems
Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes may help to lower the risk of serious kidney problems, according to a Scandinavian study led by researchers at Karolinska Institutet. The findings, now published in the journal The BMJ, provide support for the use of SGLT2 inhibitors in a broad range of...
Post
Diabetes drug reduces complications of long-term steroid therapy
by Queen Mary, University of London A drug used to treat type 2 diabetes could offer a simple and cheap solution to reduce dangerous side effects of steroid treatment, new research from Queen Mary University of London suggests. The phase 2 clinical trial, funded by Barts Charity, looked at the effects of the diabetes drug...
Post
In US, diabetics turn to black market or Canada for life-saving insulin
On a frosty January morning in a Minneapolis suburb, Abigail Hansmeyer leaves her car engine running and takes out a brown paper bag carrying needles and a vial, handing it over to its recipient in an anonymous shopping center parking lot. The exchange is technically illegal, but these aren’t illicit drugs. Instead, the vial contains...
Post
Wonder drug? Exploring the molecular mechanisms of metformin, a diabetes drug with Medieval roots
by Delthia Ricks , Medical Xpress At only pennies per dose, metformin is a Type 2 diabetes drug with distant roots in Medieval folk medicine and a powerful capacity to reduce body weight, fat mass, circulating glucose—and prevent the disorder altogether in people at elevated risk. New research on the most widely prescribed Type 2...
Post
Discontinuing insulin for older adults with type 2 diabetes
by Kaiser Permanente Patients with type 2 diabetes who were in poor health were more likely to continue taking insulin after age 75 than their counterparts in better health, according to Kaiser Permanente research published today in JAMA Internal Medicine. As people with type 2 diabetes age, the risks of insulin use can outweigh its...
Post
Temple scientists solve mystery underlying heart toxicity caused by diabetes drugs
TEMPLE UNIVERSITY HEALTH SYSTEM (Philadelphia, PA) – Like catching two fish with one worm, treating two problems with a single drug is efficient, but exceedingly difficult. In particular, for new diabetes medications, in which one drug aims to tackle two major complications of diabetes – the excess of both lipids and glucose in the blood – the therapeutic benefits,...
Post
A third of type one diabetes is misdiagnosed in the over 30s
More than a third of people over the age of 30 who are initially diagnosed with type 2 diabetes actually have type 1, meaning they are not receiving the right treatment, UNIVERSITY OF EXETER More than a third of people over the age of 30 who are initially diagnosed with type 2 diabetes actually have type1, meaning they are not receiving the right treatment, new research has revealed. The study, led by the University...
Post
A Cheap Diabetes Drug Shows Potential as a Life-Extension Therapy
But pharmaceutical companies have little financial incentive to research it. Off-Label Angel investor Ariel Poler thinks he’s discovered a way to live a longer, healthier life — and it’s only costing him $2 a month. Millions of people with diabetes take the drug metformin to help lower their blood sugar levels. But in recent years, Poler and a growing...
Post
Diabetes drug prevents heart failure
Boston, MA — In the largest trial to date to assess cardiovascular outcomes for an important class of diabetes medications, researchers have found that dapagliflozin markedly reduced the risk of hospitalization for heart failure in a broad population of patients with diabetes. This benefit was seen across the study population, including in patients who did...